SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Interim Management Statement

25 Jul 2018 07:00

RNS Number : 6360V
Victrex PLC
25 July 2018
 
 

 

 

 

25 July 2018

Victrex plc: Interim Management Statement

 'On track for a strong FY18'

Victrex plc, an innovative world leader in high performance polymer solutions, today releases its Interim Management Statement for the third quarter (Q3) covering the period 1 April to 30 June 2018.

Victrex has performed well since the end of the first half and cash generation has remained strong. Core business momentum has continued, with the majority of our markets in growth. Q3 saw a slightly lower contribution from the large Consumer Electronics order and with no volumes expected from this order in the fourth quarter, we will see a tougher Q4 comparative versus last year.

 

Medical revenue was in line with the prior year. Despite the challenging US Spine market, we still anticipate delivering meaningful revenue this year for our differentiated and innovative PEEK-OPTIMATM HA Enhanced product.

 

Overall, Q3 Group sales volume was up 14% to 1,161 tonnes (Q3 2017: 1,022 tonnes), with Group revenue up 10% to £84.0m (Q3 2017: £76.3m). Year to date Group sales volume of 3,417 tonnes is 19% up on the prior year (2017 YTD: 2,881 tonnes), with year to date Group revenue of £250.6m up 21% (2017 YTD: £207.3m).

Mega-programme progress

Victrex continues to focus on delivering further milestones in its growth pipeline and mega-programmes.

 

Following a commitment to deploy Magma's flexible oil & gas composite pipe by Tullow in West Africa, additional opportunities are under discussion, both with Tullow and other operators, in FY19. In Aerospace, construction of our US manufacturing facility, to support our TxV Aero Composites joint venture, is nearing completion, with prototype orders already in place. In Medical, following the agreement with Straumann Dental to enhance market access for our Juvora Dental product, we are in discussions for further customer agreements.

 

Currency

Currency remains in line with guidance for FY18, with approximately 90% of the FY18 currency benefit already seen in the first half, and a much lower benefit in the second half year. Looking ahead to 2019, over 50% of our currency hedges are in place. Although Sterling has slightly weakened since the end of our first half year, our guidance for FY19 remains similar, with an approximately £8m - £10m headwind to profits based on current rates and hedging in place, and reflecting some emerging raw material inflation.

 

Outlook

With continued momentum in our core business and milestones in our mega-programmes, we remain well positioned to continue driving growth as part of our Polymer & Parts strategy.

 

Although growth comparatives will be tougher in Q4, and we will see currency becoming a headwind, Victrex remains comfortable with full year expectations. Overall, we are on track to deliver a strong performance for FY18 as a whole.

 

 

Analyst & investor conference call

A conference call for analysts & investors will be held today, Wednesday 25 July at 08.00 BST.

Dial in details: +44 3333 000804 PIN: 96849285#

 

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations & Communications +44 (0) 7809 595831

Richard Armitage, Group Finance Director +44 (0) 1253 897700

Jakob Sigurdsson, Chief Executive +44 (0) 1253 897700

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of automotive, aerospace, energy (including manufacturing & engineering), electronics and medical. Every day, millions of people use products and applications, which contain our materials - from smart phones, aeroplanes and cars to oil and gas operations and medical devices. With over 35 years' experience, we develop world leading solutions in PEEK and PAEK based polymers, semi-finished and finished parts which shape future performance for our customers and our markets, and drive value for our shareholders. Find out more at www.victrexplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTEASXLADDPEFF
Date   Source Headline
27th Feb 201510:00 amRNSTotal Voting Rights
26th Feb 20154:53 pmRNSHolding(s) in Company
25th Feb 20154:43 pmRNSHolding(s) in Company
19th Feb 20153:03 pmRNSDirector/PDMR Shareholding
17th Feb 20152:25 pmRNSDirector/PDMR Shareholding
4th Feb 20153:59 pmRNSResult of AGM
4th Feb 20157:00 amRNSAGM and Q1 Interim Management Statement
30th Jan 20152:00 pmRNSTotal Voting Rights
26th Jan 201512:03 pmRNSDirector Declaration
19th Jan 20153:38 pmRNSDirector/PDMR Shareholding
14th Jan 20154:00 pmRNSHolding(s) in Company
5th Jan 201511:43 amRNSAnnual Financial Report
31st Dec 20147:00 amRNSTotal Voting Rights
19th Dec 20147:00 amRNSDirector Declaration
18th Dec 20148:34 amRNSDirectorate Change
18th Dec 20147:00 amRNSDirectorate Change
17th Dec 201412:45 pmRNSDirector/PDMR Shareholding
16th Dec 20145:13 pmRNSDirector/PDMR Shareholding
16th Dec 20144:43 pmRNSDirector/PDMR Shareholding
9th Dec 20147:00 amRNSFinal Results
1st Dec 20141:51 pmRNSBlocklisting Interim Review
28th Nov 201410:00 amRNSTotal Voting Rights
25th Nov 20144:30 pmRNSHolding(s) in Company
18th Nov 201411:38 amRNSDirector/PDMR Shareholding
6th Nov 201411:12 amRNSDirector Declaration
31st Oct 20149:27 amRNSTotal Voting Rights
21st Oct 20143:14 pmRNSSenior Independent Director Appointment
20th Oct 20144:38 pmRNSHolding(s) in Company
20th Oct 20149:05 amRNSDirector/PDMR Shareholding
9th Oct 20147:00 amRNSTrading Statement
1st Oct 20143:56 pmRNSDirector Disclosure Section 430 (2B)
1st Oct 20147:00 amRNSDirectorate Change
30th Sep 20141:34 pmRNSTotal Voting Rights
24th Sep 20144:12 pmRNSHolding(s) in Company
17th Sep 20141:16 pmRNSDirector/PDMR Shareholding
29th Aug 201410:00 amRNSTotal Voting Rights
19th Aug 20142:34 pmRNSDirector/PDMR Shareholding
31st Jul 20149:37 amRNSTotal Voting Rights
30th Jul 20147:00 amRNSInterim Management Statement
21st Jul 20142:13 pmRNSHolding(s) in Company
30th Jun 20142:54 pmRNSTotal Voting Rights
27th Jun 20144:00 pmRNSHolding(s) in Company
23rd Jun 201411:07 amRNSHolding(s) in Company
17th Jun 20144:04 pmRNSDirector/PDMR Shareholding
9th Jun 201411:18 amRNSBlocklisting Interim Review
4th Jun 20142:28 pmRNSDirector/PDMR Shareholding
30th May 201412:00 pmRNSTotal Voting Rights
27th May 20143:09 pmRNSDirector/PDMR Shareholding
20th May 20147:06 amRNSDirectorate Change
20th May 20147:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.